Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer

Cancer

Volumn 118, Issue 9, 2012, Pages 2385-2393

  Bayraktar, Soley ^a   Gonzalez Angulo, Ana M ^a   Lei, Xiudong ^a   Buzdar, Aman U ^a   Valero, Vicente ^a   Melhem Bertrandt, Amal ^a   Kuerer, Henry M ^b   Hortobagyi, Gabriel N ^a   Sahin, Aysegul A ^a   Meric Bernstam, Funda ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

anthracyclines; HER2 positive breast cancer; neoadjuvant therapy; pCR; survival; trastuzumab

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 84860223498     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26555     Document Type: Article

References (42)

1. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17: 460-469.
2. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z,. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995; 180: 297-306.
3. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 2672-2685.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG),. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
7. Slamon DJ, Leyland-Jones B, Shak Sl,. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
8. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ,. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004; 96: 739-749.
9. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005; 23: 4265-4274.
10. Buzdar AU, Ibrahim N, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676-3685.
11. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010; 375: 377-384.
12. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010; 28: 2024-2031.
13. American Joint Committee on Cancer. AJCC cancer staging manual and handbook. 7th ed. New York, NY: Springer; 2010.
14. The World Health Organization. The World Health Organization histological typing of breast tumors-second edition. Am J Clin Pathol. 1982; 78: 806-816.
15. Black MM, Speer FD,. Nuclear structure in cancer tissues. Surg Gynecol Obstet. 1957; 105: 97-102.
16. Therasse P, Eisenhauer EA, Verweij J,. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006; 42: 1031-1039.
17. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC), version 4.0. Bethesda, MD: National Cancer Institute; 2009.
18. Chia S, Bryce C, Pansegrau G, et al. Phase II trial of neoadjuvant chemotherapy of sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): a multi-centre study from British Columbia. Presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 5118.
19. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007; 13: 228-233.
20. Livasy C, Carey L, DeMichele A, et al. Influence of anthracycline- and taxane-based neoadjuvant chemotherapy on tumor HER2 protein expression in locally advanced breast cancers: results from the I-SPY trial (CALGB 150007/150012 & ACRIN 6657). Cancer Res. 2009; 69 (2 suppl); 97s.
21. Masuda N, Nakayama T, Matsunami N, et al. Phase II trial of neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide (FEC100) followed by weekly paclitaxel and trastuzumab (PH) for HER2 positive breast cancer (Kinki Multidisciplinary Breast Oncology Group; KMBOG-0402). Cancer Res. 2009; 69 (2 suppl); 256s.
22. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003; 21: 46-53.
23. Chang HR, Prati R, Gornbein JA, Chung D, Glaspy JA,. Survival in patients with locally advanced breast cancer after neoadjuvant docetaxel (T), carboplatin (C), and trastuzumab. J Clin Oncol. 2009; 27 (suppl):abstr e11573.
24. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007; 13: 1198-1207.
25. Hurley J, Doliny P, Silva O, et al. Neoadjuvant Herceptin/taxotere/ cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol. 2002; 21: 50a.
26. Jahanzeb M, Brufsky A, Erban J, Lewis D, Limentani S,. Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. J Clin Oncol. 2005; 23: 26S.
27. Paz IB, Lau S, Garberoglio C, et al. NAB-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III breast cancer (BC). J Clin Oncol. 2008; 26: 22s.
28. Raefsky E, Castillo R, Lahiry A, et al. Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (NAB paclitaxel) and carboplatin in HER2+ locally advanced breast cancer. J Clin Oncol. 2008; 26: 37s.
29. Wildiers H, Neven P, Christiaens M-R, et al. Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T), trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): final analysis. Cancer Res. 2009; 69 (2 suppl): 343.
30. Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol. 2009; 27: 4693-4700.
31. Bines J, Murad A, Lago S, Ferrari B, Andrade J, Abdo E,. Multicenter Brazilian study of weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer. Proc Am Soc Clin Oncol. 2003; 22: 67.
32. Chang HR, Slamon D, Prati R, et al. A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: response and cardiotoxicity. J Clin Oncol. 2006; 18S: 569s.
33. Coudert BP, Arnould L, Moreau L, et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol. 2006; 17: 409-414.
34. Coudert BP, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol. 2007; 25: 2678-2684.
35. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D,. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol. 2007; 25: 1232-1238.
36. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Cancer Res. 2009; 69: 500s.
37. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006; 24: 1831-1838.
38. Chumsri S, Jeter S, Jacobs LK, et al. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer. 2010; 10: 40-45.
39. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26: 1231-1238.
40. Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res. 2009; 69:abs 80.
41. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23: 7811-7819.
42. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)/paclitaxel (T) versus AC/T with trastuzumab (H).